Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says [Yahoo! Finance]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Yahoo! Finance
Bank of America has initiated coverage of Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and a $244 price target, citing the company's royalty-focused business model and diversified portfolio as key drivers of continued earnings growth. Ligand provides capital and technology to drug and medical device developers in exchange for royalties, creating a portfolio of more than 100 commercial and development-stage assets that generate high-margin returns. In its initiation report, Bank of America analysts wrote that the company's model allows it to generate “diversified, high margin returns” while offering investors exposure to the biopharma sector with lower risk. “We believe Ligand can continue to deliver EPS growth, offering investors a way to capture biopharma's upside with less risk,” they wrote. Ligand has posted strong share and earnings growth since transitioning to its current strategy in 2022, supported by a lean cost structure and growing demand across the in
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand Pharmaceuticals (LGND) is now covered by Bank of America Corporation. They set a "buy" rating and a $244.00 price target on the stock.MarketBeat
- How The Ligand Pharmaceuticals (LGND) Story Is Shifting Around QTORIN And Royalty Growth [Yahoo! Finance]Yahoo! Finance
- Ligand to Participate in March Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Ligand to Participate in March Investor ConferencesGlobeNewswire
- Ligand Pharmaceuticals (LGND) Is Up 7.8% After Swing to Profit and New ATM Offering Filed – Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
LGND
Earnings
- 2/26/26 - Beat
LGND
Sec Filings
- 3/13/26 - Form 4
- 3/11/26 - Form 144
- 3/6/26 - Form 4
- LGND's page on the SEC website